Latest Conference Articles

Medication reconciliation at the time of admission as well as at patient discharge can prevent significant harm from adverse drug events, yet many providers feel they don't have time to take this important step.

While past studies suggest variability in physicians' chronic pain treatment decisions based on patients' sex and race, few have considered the degree of providers' self-insight into the influence of such demographics on their treatment decisions.

The TIRF REMS Access program is designed to streamline the prescribing process and ensure appropriate patients are safely provided with TIRF products, but it may be preventing patients from accessing needed medications.

Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.

News and updates about the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers.

News and updates about the 2013 American Pain Society Annual Meeting.

Understanding and addressing these disorders can improve the patient's mental health as well as their chronic pain and other comorbid conditions. Incorporating cognitive behavioral therapy and mindfulness-based cognitive therapy into the management of chronic pain has been shown to improve pain outcomes.

Study results suggest that oxidative stress may play a direct role in the neurodegeneration that occurs in ALS.

Study shows levetiracetam, carbamazepine, and topiramate are equally safe and effective in the treatment of adult patients with epilepsy induced by MELAS. However, valproate was found to be less effective and associated with more adverse events.

Researchers successfully treated a patient with refractory complex regional pain syndrome by inducing a coma with ketamine and dexmedetomidine.

More than 90% of participants in the Therapy Optimization in Multiple Sclerosis (TOP MS) study were still on their original disease modifying therapy at one year follow-up.

In the MOTION and SETTLE studies, safinamide was shown to be effective in the treatment of patients with Parkinson's disease as add-on therapy to a stable dose of a single dopamine agonist and as add-on therapy for patients taking levodopa.

News and updates about AAN 2013, the 65th Annual Meeting of the American Academy of Neurology.

News and updates about ACC.13, the 2013 Scientific Session of the American College of Cardiology.

Results from the RELAX-AHF show serelaxin reduces cardiovascular deaths and improves symptoms in patients with heart failure.

Results from a substudy of the PLATO trial show that patients with extensive CAD and high rates of recurrent cardiovascular events, death, and bleeding may benefit from treatment with ticagrelor.

Results from a sub-study of the Trial to Assess Chelation Therapy (TACT) that focused on quality of life issues in patients who had previously suffered a heart attack and were treated with chelation therapy reveal no improvements in these patients' quality of life.

Results from the TEMPO trial presented at Kidney Week 2012 show that treatment with tolvaptan slowed the increase in total kidney volume and the decline in kidney function in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Increasing numbers of people are on kidney transplant waiting lists. However, the number of potential living donors may shrink as more Americans qualify as pre-diabetic, making them less than ideal donor candidates.

Experts at Kidney Week 2012 discuss several treatment options for hyponatremia, including fluid restriction, loop diuretics, and the use of selective vasopressin V2-receptor antagonists.

A diet rich in highly alkaline fruits and vegetables helps reduce a marker of kidney injury and preserve kidney function in patients with chronic kidney disease.

Use of peritoneal dialysis in patients with end-stage renal disease is declining due to lack of physician training and awareness, financial disincentives, and other factors. However, with proper patient and provider education, it is possible to grow a successful peritoneal dialysis program.

Click here for information about registration, scheduled events and speakers, and more at IDWeek 2012.

New formulation associated with delayed time to impending relapse, as well as improvements on measures of symptom severity and treatment response.

New validated assessment tools allow clinicians to better assess the level of real-life functioning in patients with schizophrenia.

Cholestyramine and activated charcoal can be used to virtually eliminate the long half-life oral investigational multiple sclerosis drug, teriflunomide, from the plasma in 11 days.

Mark F. Mehler, MD, discussed how brain and behavior are becoming better understood through the emerging discipline of epigenetics.

Those who treat autoimmune diseases such as MS, much has been expected from stem cell research, and an ongoing study at the University of Cambridge, UK, has become a focus of high hopes.